Results
Trial
Research Area
Duration
Locations
Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious…
Open and enrolling
Tuberculosis
A5385: An Observational Post-Intervention Cohort Destination Protocol
This study is a two-step, non-interventional extension study for individuals participating in another interventional HIV cure trial (parent study) that…
Open and enrolling
Treatment Experienced
Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment…
Open and enrolling
HIV Cure
Maximum of 2 years. Arm A will receive one dose of N-803 at Week 1 and then every 3 weeks for a total of eight doses.
Scientists are looking for ways to minimize the distribution of HIV-1 in the body, especially where anti-HIV medications (ART) are…
Active, Not Recruiting
Treatment Naïve
Between 2 and 5 years.
A5391: Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide
Weight gain after starting HIV therapy is common, but recent studies have found that some people with HIV (PWH) who…
Closed to accrual
HIV comorbidities and complications
Participants will be on study treatment for 48 weeks.
Effective tuberculosis (TB) treatment is available and saves millions of lives, but it has not had a significant impact on…
Active, Not Recruiting
Tuberculosis
Participants may be in the study for up to 18 months. They will be followed for a minimum of one year following completion of TB treatment.
A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies
A master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with…
Closed to accrual
COVID-19 and Mpox
28 days of intensive follow-up, followed by limited follow-up through 24 weeks.
Transgender women (TW) are the fastest-growing group of people with HIV. Historically, TW have had few opportunities to participate in…
Open and enrolling
Treatment Experienced
Participants will complete about seven (7) visits over the course of 1 year.
A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Subsequent Vaccine
Right now there is no medicine proven to treat COVID-19 in people who are not sick enough to be hospitalized.…
Closed to accrual
COVID-19 and Mpox
A5406 is a study for people with pulmonary drug-sensitive (DS) tuberculosis (TB) without evidence of resistance to the TB drugs…
Open and enrolling
Tuberculosis
Participants will be in this study for about 48 weeks. This includes 17 weeks of anti-TB study treatment, and ART from week 6 to week 48.